Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis

Inclusion Criteria:

• Patient with moderate-to-severe chronic plaque psoriasis who has involved body surfacearea (BSA) ≥ 10% (Palm Method), ≥ 12 on the PASI, and static Physicians GlobalAssessments (sPGA) ≥ 3 (moderate) at Screening and at BL.

• Patient has had stable psoriatic disease for at least 2 months (ie, withoutsignificant changes as defined by the Investigator or designee).

• Patient is a candidate for systemic therapy and the patient has a previous failure,inadequate response, intolerance, or contraindication to at least 1 systemicantipsoriatic therapy including, but not limited to, methotrexate, cyclosporine,psoralen plus ultraviolet light A (PUVA), and ultraviolet light B (UVB).

Exclusion Criteria:

• Patient has prior use of 2 or more biologics for treatment of PsO.

• Patient diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis,medication-induced psoriasis, other skin conditions (eg, eczema), or other systemicautoimmune disorder inflammatory disease at the time of the Screening visit that wouldinterfere with evaluations of the effect of the study drug on psoriasis.

• Patient has prior use of any of the following medications within specified timeperiods or will require use during the study:

1. Topical medications within 2 weeks of BL (Week 1).

2. PUVA phototherapy and/or UVB phototherapy within 4 weeks prior to the BL Visit.

3. Nonbiologic psoriasis systemic therapies (eg, cyclosporine, methotrexate, andacitretin) within 4 weeks prior to the BL Visit.

4. Any prior or concomitant or biosimilar adalimumab therapy, either approved orinvestigational.

5. Any systemic steroid in the 4 weeks prior to BL. Note: Only key inclusion/exclusion criteria mentioned here. Patients will be screened andrandomized per the list in the protocol